Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


516.000 DKK 49.800 10.68%

As of 12:04:59 ET on 03/27/2015.

Snapshot for Genmab A/S (GEN)

Open: 495.000 Day's Range: 495.000 - 519.500 Volume: 1,017,442
Previous Close: 466.200 52wk Range: 180.100 - 558.000 1-Yr Rtn: +129.33%

Stock Chart for GEN

No chart data available.
  • GEN:DC 516.000
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 95.1064
Estimated P/E(12/2015) 95.2557
Relative P/E vs. KFX 3.2137
Earnings Per Share (DKK) (ttm) 5.4255
Est. EPS (DKK) (12/2015) 5.4170
Est. PEG Ratio 2.0336
Market Cap (M DKK) 29,996.97
Shares Outstanding (M) 58.13
30 Day Average Volume 343,700
Price/Book (mrq) 14.4595
Price/Sale (ttm) 34.1240
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil